Dapagliflozin preferentially reduces fibrosis biomarkers in chronic heart failure patients with high extracellular matrix remodeling activity

10 May 2026 (13:38 - 14:55)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - pathophysiology and mechanisms (3) Ventricular Remodelling HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

ESC 365 is supported by

ESC 365 is supported by